Swecure is developing treatments for immunoregulatory disorders, such as allergy and Inflammatory bowel disease (IBD)
Swecure is developing treatments for immunoregulatory disorders, such as allergy and Inflammatory bowel disease (IBD). Its lead products which are in preclinical development are: SWE01 - a bacterial protein with the unique ability to activate immunological tolerance mechanisms to prevent allergy; SWE02 - a composition of good bacteria to restore the gut microbial dysbiosis in order to relieve inflammation in patients with IBD.